AlphaGen
Access AlphaGen
Company Narratives

IBL HealthCare Q3 FY26: Margins Accelerate, but Receivables Hold Back Cash Conversion

IBL HealthCare’s Q3 sales and margins accelerated sharply, but receivables growth and heavier short-term borrowing kept cash conversion weak.

Sep 22, 2026IBLHLShare price, results & dividends

Verdict

IBL HealthCare Limited’s Q3 FY26 was the strongest quarter of the first nine months of the year. Revenue rose 27.9% year on year to Rs1.213 billion, gross profit increased 41.3% to Rs442.8 million and profit after tax rose 74.6% to Rs61.9 million. Gross margin widened by about 3.5 percentage points to 36.5%, while finance cost fell 26.2%. The quarter therefore combined faster sales growth, better unit economics and a lighter financing burden.

The nine-month result is more nuanced. Revenue increased only 5.1% to Rs3.305 billion, but gross profit rose 26.0% and gross margin expanded to 37.7% from 31.4%. Management attributes the improvement to a focus on profitable product portfolios, selective pricing and procurement efficiencies. The revenue bridge also matters: gross sales actually declined 2.5%, but sales returns and discounts fell sharply, allowing net revenue to grow. That points to better revenue quality and commercial discipline rather than a simple volume surge.

The main weakness is cash conversion. Despite Rs167.5 million of nine-month profit after tax, operating cash flow remained negative at Rs389.8 million. Trade and other receivables absorbed Rs616.3 million of cash and rose to Rs2.313 billion at March 31, while short-term borrowings climbed to Rs435.9 million from Rs136.4 million at June 2025. Inventory fell materially and the current ratio remained around 2.0 times, so this is primarily a working-capital issue. The next result cycle should be judged on whether stronger margins begin to convert into cash.

Company and reporting basis

Company Name: IBL HealthCare Limited

Ticker: IBLHL

Reporting period: Quarter and nine months ended March 31, 2026

Reporting basis: Unaudited company-only condensed interim financial statements, presented in Pakistani rupees with statement figures in thousands. The March 31, 2026 statement of financial position is compared with the audited June 30, 2025 balance sheet. The Board considered the third-quarter results on April 28, 2026; PSX announced the financial result on April 29 and recorded transmission of the quarterly report on April 30, 2026.

IBL HealthCare’s principal activities are the marketing, selling and distribution of healthcare and consumer products. This matters when interpreting sector data: the company is primarily a commercial and distribution platform rather than a pure manufacturing operation, so pharmaceutical production trends are useful context but not a direct proxy for its sales.

AlphaGen model outputs

Alpha QoQ Score: 72.32

TTM Performance Score: 88.39

3Y Business Perf Score: 53.85

Sector Leadership Score: 61.3368

These four scores are AlphaGen model outputs, not figures reported by IBL HealthCare Limited.

Results at a glance

  • Q3 revenue increased 27.9% to Rs1.213 billion from Rs948.0 million. Gross profit rose 41.3% to Rs442.8 million, lifting gross margin to 36.5% from 33.0%.
  • Marketing and distribution expense increased 23.8% to Rs245.0 million and administrative expense increased 64.1% to Rs55.2 million, but gross-profit growth more than absorbed the higher operating spend.
  • Q3 finance cost fell 26.2% to Rs11.4 million. Profit before levies and income tax more than doubled to Rs133.1 million, while PAT rose 74.6% to Rs61.9 million. EPS increased to Rs0.63 from a restated Rs0.36.
  • For 9MFY26, revenue increased 5.1% to Rs3.305 billion, gross profit rose 26.0% to Rs1.245 billion and PAT increased 23.6% to Rs167.5 million. Nine-month gross margin expanded to 37.7% from 31.4%.
  • Operating cash flow remained negative at Rs389.8 million, although this improved from a Rs674.6 million outflow. Receivables were the largest working-capital drag.
  • Short-term borrowings rose to Rs435.9 million from Rs136.4 million at June 2025, while cash fell to Rs111.9 million from Rs208.9 million. Current assets still covered current liabilities by about 2.0 times.

What improved

The March quarter marked a clear acceleration from the first half. Derived from the reported nine-month and Q3 figures, first-half FY26 revenue was about 4.8% lower year on year, whereas Q3 revenue increased 27.9%. First-half PAT had grown only about 5.6%; Q3 PAT then rose 74.6%. The year-to-date result therefore understates how much stronger the latest quarter was than the earlier part of FY26.

The biggest operational improvement was gross profitability. Q3 gross margin rose to 36.5% from 33.0%, while the nine-month margin rose to 37.7% from 31.4%. Management explicitly links the nine-month improvement to profitable product selection, selective pricing and procurement efficiencies. Cost of sales fell 4.5% over the nine months even as net revenue increased 5.1%.

The revenue bridge is particularly revealing. Nine-month gross sales were Rs4.131 billion, 2.5% below the prior-year Rs4.238 billion. Sales returns fell to Rs120.7 million from Rs217.9 million and sales discounts fell to Rs355.5 million from Rs499.8 million. Combined returns and discounts therefore declined by about Rs241.5 million, more than offsetting the decline in gross sales and helping net revenue rise by Rs160.1 million. Economically, the company retained more of each rupee invoiced, consistent with management’s emphasis on profitable portfolios and selective pricing.

Finance cost also improved. Nine-month finance cost declined 33.0% to Rs32.6 million and Q3 finance cost fell 26.2% to Rs11.4 million. The notes show markup on musharakah finance fell to Rs29.9 million from Rs47.0 million for the nine months. Management cites lower policy rates and improved cash management. The State Bank of Pakistan kept the policy rate at 10.5% in March 2026 after substantial prior easing, which supports the direction of management’s explanation. The filing does not provide a full rate-versus-volume bridge, so lower rates should not be treated as the sole cause.

Other income turned modestly favorable at Rs8.6 million from a Rs1.4 million loss, helped by a Rs4.6 million exchange gain versus a Rs4.1 million exchange loss and higher rental income. These amounts supported earnings but were too small to drive the result.

What weakened / needs attention

Operating expenses rose quickly. Nine-month marketing and distribution expense increased 28.2% to Rs748.0 million and administrative expense increased 39.0% to Rs141.5 million. Management describes this as strategic investment in brand development, channel expansion and enhanced market coverage. That may support future growth, but it also means a meaningful share of the gross-margin gain is being reinvested rather than falling directly to the bottom line.

The tax line was unusually heavy. Nine-month income tax expense rose to Rs163.8 million from Rs92.3 million and included a Rs43.0 million prior-year charge, which is non-recurring with respect to current-period operating performance. The comparative also carried Rs24.8 million of minimum-tax levies separately above profit before taxation, while no such levy was reported in 9MFY26. These effects help explain why profit before taxation rose 45.4% but PAT increased only 23.6%.

Working capital is the clearest financial weakness. Trade and other receivables rose 36.3% from June 2025 to Rs2.313 billion, while loans, advances, deposits and prepayments nearly doubled to Rs214.3 million. In the cash-flow statement, receivables absorbed Rs616.3 million and those other working-capital items absorbed another Rs106.5 million. Inventory released Rs245.9 million of cash, but that was not enough to offset the build elsewhere.

The financing response is visible on the balance sheet. Short-term borrowings increased 219.7% from June to Rs435.9 million. The company had Rs439 million of running musharakah facilities, of which only about Rs3.1 million was unavailed at March 31. Cash fell 46.5% to Rs111.9 million. The current ratio remained near 2.0 times, but the business became more reliant on short-term financing to fund working capital.

Cash flow and balance-sheet quality

Nine-month cash used in operating activities improved to Rs389.8 million from Rs674.6 million, a year-on-year improvement of about Rs284.8 million. Even so, reported profit is not yet being converted into operating cash. Before tax and finance payments, operations showed a Rs206.6 million cash deficit because working-capital absorption outweighed profit and non-cash adjustments.

Financing cash flow was positive Rs297.5 million. The company obtained Rs3.692 billion of short-term loans and repaid Rs3.392 billion during the nine months, leaving a net borrowing inflow of roughly Rs299.6 million before lease payments and dividends. As an inference, this rolling use of short-term facilities is consistent with the working-capital demands of receivables and inventory, but it raises sensitivity to collection cycles and financing conditions.

The balance sheet still has buffers. Current assets were Rs3.694 billion against current liabilities of Rs1.835 billion, total equity was Rs2.491 billion and total assets were Rs4.343 billion. Inventory declined 19.4% from June, which is constructive. Capital expenditure was only Rs4.8 million, reinforcing that the cash-flow issue is primarily working capital rather than heavy fixed-asset investment.

Recurring versus non-recurring earnings drivers

  • Recurring / operational: distribution revenue, product mix, selective pricing, procurement efficiency and the associated marketing and administrative cost base are the main recurring earnings drivers.
  • Recurring but rate-sensitive: finance cost is part of the normal working-capital funding model. Lower benchmark rates helped, but the larger borrowing balance keeps financing costs important.
  • Period-specific: the Rs43.0 million prior-year income-tax charge depressed 9MFY26 PAT and should not be treated as a normal operating cost of the current period.
  • Comparability item: the prior-year nine months included Rs24.8 million of minimum-tax levies, while the current period reported none. Recurrence depends on tax circumstances rather than operating execution.

What changed versus the historical pattern

The most important change inside FY26 is that growth became much more visible in Q3. The first half had lower revenue year on year, while the March quarter delivered nearly 28% growth. At the same time, the margin improvement built through product selection, selective pricing and procurement remained in place. The combination of renewed top-line momentum and higher gross margin is stronger than a result driven by cost cuts alone.

The broader sector backdrop was mixed. Pakistan’s overall large-scale manufacturing output grew 6.48% in July–March FY2026, but the Pakistan Economic Survey reports pharmaceutical manufacturing down 5.14% in FY2026. Since IBL HealthCare is a marketer and distributor rather than a pure manufacturer, that decline is not a direct demand measure. It does show, however, that IBLHL’s improved net revenue and margins were not simply the mechanical result of a booming domestic pharmaceutical production cycle.

Abbott Pakistan offers a useful listed-peer cross-check. Abbott reported only 2% overall Q1 2026 sales growth, with pharmaceutical sales up 6%, while gross margin improved to 38% from 34% because of cost optimization and efficiency measures. The comparison is not perfectly like-for-like, but it suggests margin improvement through mix and efficiency was possible across parts of healthcare even as demand conditions remained uneven. As an inference, IBL HealthCare’s much faster Q3 sales growth appears at least partly company-specific rather than purely sector-driven.

Corporate actions

The Board did not declare a cash dividend, bonus issue, rights issue or other distribution with the Q3 result. Separately, during FY26 the company issued bonus shares in the ratio of 15 shares for every 100 shares held, increasing paid-up capital to Rs985.3 million from Rs856.7 million. The bonus issue is a non-cash equity reclassification and does not change the underlying economics of the quarter.

Key risks

  • Receivables and collection risk: trade and other receivables reached Rs2.313 billion and were the largest source of operating cash absorption.
  • Short-term funding dependence: borrowings rose sharply and almost the entire Rs439 million musharakah facility was utilized at March 31.
  • Expense productivity: marketing and administrative costs are growing much faster than nine-month revenue, so future sales growth must justify the added spend.
  • Tax volatility: the prior-year tax charge and different minimum-tax presentation make the effective tax burden noisy.

What to monitor next

  • Revenue momentum: whether Q3’s acceleration is sustained after a first half in which revenue was lower year on year.
  • Gross margin: whether the roughly 36–38% range can be maintained as product mix, pricing and procurement conditions change.
  • Receivable conversion: whether receivables stabilize or decline and operating cash flow moves toward positive territory.
  • Borrowings and finance cost: whether short-term debt falls as collections improve, or higher facility utilization offsets the benefit of lower benchmark rates.
  • Operating expense productivity and tax normalization: both will determine how much gross-profit growth reaches shareholders.

Bottom line

IBL HealthCare delivered a genuinely stronger Q3 FY26. Sales growth accelerated sharply, gross margin expanded, finance cost declined and PAT grew almost 75%. The nine-month revenue bridge also suggests better commercial quality: lower returns and discounts allowed net sales to increase despite lower gross billings. Combined with management’s stated focus on profitable portfolios, selective pricing and procurement efficiencies, the improvement looks operational rather than dependent on a large one-off gain.

The unresolved issue is cash. Receivables grew much faster than revenue, operating cash flow remained negative and short-term borrowing increased substantially. Current assets still exceed current liabilities and equity remains positive, but those buffers do not resolve weak cash conversion. The next result cycle needs to show that stronger accounting margins can translate into collections, lower borrowing requirements and ultimately positive operating cash generation.

Sources

Explore more research

All articles